Kappa Opioid Receptor Imaging in Post-traumatic Stress Disorder (PTSD)

Exclusion Criteria

• •1. any primary Axis I disorder other than PTSD (e.g. psychosis)
• •2. medical or neurological illnesses likely to affect physiology or anatomy, i.e. uncontrolled hypertension, cardiovascular disorders
• •3. a history of drug (including benzodiazepines (BZD)) dependence (Diagnostic and Statistical Manual of Mental Disorders (DSM IV) criteria) within 1 year of the study and lasting longer than 2 years, except for alcohol dependence
• •4. current pregnancy (as documented by pregnancy testing at screening or on the day of PET imaging study)
• •5. current breast feeding
• •6. use of tobacco- or nicotine-containing products in excess of the equivalent of 5 cigarettes per day, or cannot abstain from smoking during the prescribed tests
• •7. acute suicidal ideation or behavior, as defined by suicidal ideation and behavior during the 3-month period prior to enrollment in the study and while being enrolled in the study
• •9. Human immunodeficiency virus (HIV) (due to possible neuropsychiatric effects);
• •10. use of opioid medications within 2 weeks of the PET study
• •11. having an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participation in the study
• •12. seriously claustrophobic
• •13. blood donation within 8 weeks prior to the study.
• •1. any history or current primary Axis I disorder
• •2. medical or neurological illnesses likely to affect physiology or anatomy, i.e. uncontrolled hypertension, cardiovascular disorders
• •3. a history of drug (including benzodiazepines \[BZD\]) dependence (DSM IV criteria) within 1 year of the study and lasting longer than 2 years, except for alcohol dependence
• •4. current pregnancy (as documented by pregnancy testing at screening or on the day of PET imaging study)
• •5. current breast feeding
• •6. use of tobacco- or nicotine-containing products in excess of the equivalent of 5 cigarettes per day, or cannot abstain from smoking during the prescribed tests
• •7. acute suicidal ideation or behavior, as defined by suicidal ideation and behavior during the 3-month period prior to enrollment in the study and while being enrolled in the study
• •9. HIV (due to possible neuropsychiatric effects)
• •10. use of opioid medications within 2 weeks of the PET study
• •11. having an abnormality in the 12-lead ECG that, in the opinion of the investigator, increases the risks associated with participation in the study
• •12. seriously claustrophobic
• •13. blood donation within 8 weeks prior to the study